New bladder cancer drug trial aims to find safe dose
NCT ID NCT06637423
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 30 times
Summary
This early-stage study tests a drug called Sacituzumab Tirumotecan (Sac-TMT) given directly into the bladder for people with intermediate-risk non-muscle invasive bladder cancer that has come back. The main goals are to check the drug's safety and find the highest dose people can tolerate. About 32 participants will be enrolled to help guide future studies on how well the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CIUSSS de l'Estrie-CHUS ( Site 0002)
RECRUITINGSherbrooke, Quebec, J1H 5N4, Canada
Contact Phone: •••-•••-••••
-
Erasmus Medisch Centrum ( Site 0032)
RECRUITINGRotterdam, South Holland, 3015 GD, Netherlands
Contact Phone: •••-•••-••••
-
Gustave Roussy ( Site 0013)
RECRUITINGVillejuif, Val-de-Marne, 94805, France
Contact Phone: •••-•••-••••
-
HENRI MONDOR HOSPITAL ( Site 0011)
RECRUITINGCréteil, Val-de-Marne, 94010, France
Contact Phone: •••-•••-••••
-
Hospital Universitario 12 de Octubre ( Site 0042)
RECRUITINGMadrid, 28041, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario Virgen de la Victoria ( Site 0043)
RECRUITINGMálaga, Andalusia, 29010, Spain
Contact Phone: •••-•••-••••
-
Hôpital Claude Huriez ( Site 0012)
RECRUITINGLille, Nord, 59037, France
Contact Phone: •••-•••-••••
-
Johns Hopkins University ( Site 0055)
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-••••
-
Michael G Oefelein Clinical Trials ( Site 0053)
RECRUITINGBakersfield, California, 93301, United States
Contact Phone: •••-•••-••••
-
Moffitt Cancer Center ( Site 0057)
RECRUITINGTampa, Florida, 33612, United States
Contact Phone: •••-•••-••••
-
Northwestern University ( Site 0051)
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-••••
-
Princess Margaret Cancer Centre ( Site 0003)
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
-
St Bartholomew s Hospital ( Site 0061)
RECRUITINGLondon, London, City of, EC1A 7BE, United Kingdom
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.